 "Dr Reddy's ties up with Turkish firm TR-Pharm for biosimilars")
Dr Reddy’s Laboratories Ltd has entered into a strategic collaboration agreement with Turkey-based TR-Pharm involving three biosimilar products. A total of three products will be registered and subsequently commercialised as a part of this agreement by TR-Pharm in Turkey. TR-Pharm will also manufacture the drug substance and drug product upon completion of its facility investment.
Mehmet Goker, general manager of TR-Pharm, said, “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country. We are pleased to have already started laying out the groundwork for manufacturing with Dr Reddy’s for high quality biosimilar products.”
TR-Pharm has begun laying out the groundwork for the technology transfer. This collaboration will be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region. The partnership will also enable Dr Reddy’s to widen the global footprint of its biosimilar business.
M V Ramana, executive vice president & head branded markets (India and emerging countries), said, “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products. Dr Reddy’s Laboratories is and remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey.”
TR Pharm is a pharma start-up focused on innovation with investments into R&D and a cutting edge biotechnological manufacturing capability with the aim of becoming a regional commercial player based out of Turkey. TR Pharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA region besides the local market. TR Pharm has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases.
Mehmet Goker, general manager of TR-Pharm, said, “Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country. We are pleased to have already started laying out the groundwork for manufacturing with Dr Reddy’s for high quality biosimilar products.”
TR-Pharm has begun laying out the groundwork for the technology transfer. This collaboration will be an important component of TR-Pharm’s ongoing biological product development and manufacturing business in the region. The partnership will also enable Dr Reddy’s to widen the global footprint of its biosimilar business.
M V Ramana, executive vice president & head branded markets (India and emerging countries), said, “Turkey is a key emerging market and we are pleased to partner with TR-Pharm to ensure that patients in the region get access to our portfolio of high quality biosimilar products. Dr Reddy’s Laboratories is and remains committed to providing access to affordable and innovative drugs to populations around the world, and this partnership will make this happen in Turkey.”
TR Pharm is a pharma start-up focused on innovation with investments into R&D and a cutting edge biotechnological manufacturing capability with the aim of becoming a regional commercial player based out of Turkey. TR Pharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA region besides the local market. TR Pharm has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%